You are here: Industry Insights > acquisition

News List

J&J completes acquisition of Auris Health biospectrumasia
April 04, 2019
Johnson & Johnson announced that its subsidiary Ethicon has completed the acquisition of Auris Health for approximately $3.4 billion in cash.
Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre worldpharmanews
April 04, 2019
Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre
Sterling Pharma Aquires CiVentiChem in the US contractpharma
April 03, 2019
Enhance chemistry development capabilities to support pre-clinical and early phase clinical supply
ResMed completes acquisition of HB Healthcare biospectrumasia
March 15, 2019
ResMed acquires HB Healthcare to help millions of Koreans living with sleep apnea, other respiratory conditions
BASi Appoints Key Executive contractpharma
March 08, 2019
Scott Daniels, PhD joins as senior vice president of DMPK, effective as of March 1, 2019
AGC Completes Acquisition of Spanish Synthetic Pharmaceutical Active Ingredient Manufacturer Malgrat Pharma Chemicals en-cphi.cn
March 07, 2019
AGC Inc. based in Tokyo announced on March 4 the completion of its acquisition of Spain's synthetic pharmaceutical active ingredient manufacturer, Malgrat Pharma Chemicals, S.L.U. (hereinafter referred to as MPC).
AGC completes acquisition of Malgrat Pharma Chemicals biospectrumasia
March 04, 2019
The acquisition of MPC has allowed the AGC Group to obtain another manufacturing and sales base outside of Japan, following the acquisitions of two biopharmaceutical CDMO companies, Biomeva (2016) and CMC Biologics (2017)
Ipsen to buy rare disease firm Clementia for up to $1.31bn pharmaphorum
February 26, 2019
France’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to $1.31 billion.
Merck agrees to acquire Immune Design for $300m pharmaceutical-technology
February 26, 2019
Merck has reached an agreement to acquire all outstanding shares of US-based late-stage immunotherapy firm Immune Design in an all cash deal valued at approximately $300m, or $5.85 per share....
Roche to acquire gene therapy specialist Spark Therapeutics for $4.8bn pharmaceutical-technology
February 26, 2019
Roche has signed a definitive merger agreement to acquire all outstanding shares of US-based gene therapy company Spark Therapeutics for $114.50 per share....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page